FRESH TRACKS THERAPEUTICS IN (FRTX) Stock Price, Quote, News and Overview
NASDAQ:FRTX - Nasdaq - US10802T2042 - Common Stock - Currency: USD
FRTX Quote, Performance and Key Statistics
0.79
-0.02 (-2.48%)
The current stock price of FRTX is 0.79 USD. In the past month the price decreased by -4.76%. In the past year, price decreased by -42.75%.
FRTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About FRTX
Company Profile
Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 13 full-time employees. The firm is engaged in transforming patient lives through the development of differentiated prescription therapeutics. Its pipeline is focused on providing existing treatment paradigms and features several new chemical entities that inhibit novel targets with potential for autoimmune, inflammatory, and other debilitating diseases. The Company’s strategy is exploring therapies by identifying, pursuing, and developing therapeutics that can help people struggling with autoimmune, inflammatory, and other debilitating diseases. Its pipeline includes FRTX-02, FRTX-10, Next-Generation Kinase Inhibitors and FRTX-03. FRTX-02 is a potential Oral DYRK1A Inhibitor for the treatment of autoimmune and inflammatory diseases. Its FRTX-10 is a covalent Stimulator of Interferon Genes (STING) inhibitor candidate for the potential treatment of autoimmune, inflammatory, and rare genetic diseases.
Company Info
FRESH TRACKS THERAPEUTICS IN
5777 Central Ave Ste 102
Boulder COLORADO US
Employees: 13
Company Website: https://www.frtx.com/
Phone: 17205054755
FRESH TRACKS THERAPEUTICS IN / FRTX FAQ
What is the stock price of FRESH TRACKS THERAPEUTICS IN today?
The current stock price of FRTX is 0.79 USD. The price decreased by -2.48% in the last trading session.
What is the ticker symbol for FRESH TRACKS THERAPEUTICS IN stock?
The exchange symbol of FRESH TRACKS THERAPEUTICS IN is FRTX and it is listed on the Nasdaq exchange.
On which exchange is FRTX stock listed?
FRTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for FRESH TRACKS THERAPEUTICS IN stock?
7 analysts have analysed FRTX and the average price target is 4.59 USD. This implies a price increase of 481.01% is expected in the next year compared to the current price of 0.79. Check the FRESH TRACKS THERAPEUTICS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is FRESH TRACKS THERAPEUTICS IN worth?
FRESH TRACKS THERAPEUTICS IN (FRTX) has a market capitalization of 4.72M USD. This makes FRTX a Nano Cap stock.
How many employees does FRESH TRACKS THERAPEUTICS IN have?
FRESH TRACKS THERAPEUTICS IN (FRTX) currently has 13 employees.
What are the support and resistance levels for FRESH TRACKS THERAPEUTICS IN (FRTX) stock?
FRESH TRACKS THERAPEUTICS IN (FRTX) has a support level at 0.78 and a resistance level at 0.89. Check the full technical report for a detailed analysis of FRTX support and resistance levels.
Is FRESH TRACKS THERAPEUTICS IN (FRTX) expected to grow?
The Revenue of FRESH TRACKS THERAPEUTICS IN (FRTX) is expected to decline by -58.02% in the next year. Check the estimates tab for more information on the FRTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy FRESH TRACKS THERAPEUTICS IN (FRTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FRTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FRTX, evaluating the profitability, health, valuation and growth aspects
- FRESH TRACKS THERAPEUTICS IN (FRTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- FRESH TRACKS THERAPEUTICS IN (FRTX) Sales and EPS estimates to see what analysts future expectations are.
- FRESH TRACKS THERAPEUTICS IN (FRTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- FRESH TRACKS THERAPEUTICS IN (FRTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- FRESH TRACKS THERAPEUTICS IN (FRTX) Stock Chart to make your own analysis
- FRESH TRACKS THERAPEUTICS IN (FRTX) Latest news and press-releases to stay up to date.
Does FRESH TRACKS THERAPEUTICS IN (FRTX) stock pay dividends?
FRTX does not pay a dividend.
When does FRESH TRACKS THERAPEUTICS IN (FRTX) report earnings?
FRESH TRACKS THERAPEUTICS IN (FRTX) will report earnings on 2024-03-28, after the market close.
What is the Price/Earnings (PE) ratio of FRESH TRACKS THERAPEUTICS IN (FRTX)?
FRESH TRACKS THERAPEUTICS IN (FRTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.67).
What is the Short Interest ratio of FRESH TRACKS THERAPEUTICS IN (FRTX) stock?
The outstanding short interest for FRESH TRACKS THERAPEUTICS IN (FRTX) is 0.01% of its float. Check the ownership tab for more information on the FRTX short interest.
FRTX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to FRTX. When comparing the yearly performance of all stocks, FRTX is a bad performer in the overall market: 89.63% of all stocks are doing better.
FRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FRTX. FRTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
FRTX Financial Highlights
Over the last trailing twelve months FRTX reported a non-GAAP Earnings per Share(EPS) of -2.67. The EPS increased by 68.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.63% | ||
| ROE | -82.48% | ||
| Debt/Equity | 0 |
FRTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to FRTX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 5.44% and a revenue growth -58.02% for FRTX